PT 001 - Pandion Therapeutics

Alternative Names: MAdCAM PD-1 agonist; MAdCAM-tethered PD-1 Agonist; PD-1 MAdCAM Bifunctional Antibody; PD-1A07T; PT-001 - Pandion Therapeutics

Latest Information Update: 05 Apr 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pandion Therapeutics
Class Antihyperglycaemics; Bispecific antibodies; Recombinant fusion proteins
Mechanism of Action Immunomodulators; Programmed cell death 1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Apr 2021 Pandion Therapeutics has been acquired by Merck & Co
22 Feb 2021 Preclinical trials in Type 1 diabetes mellitus in USA (IV) before February 2021
22 Feb 2021 Preclinical trials in Type 1 diabetes mellitus in USA (SC) before February 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com